Catalyst Pharmaceuticals Future Growth

Future criteria checks 5/6

Catalyst Pharmaceuticals is forecast to grow earnings and revenue by 20.9% and 13.3% per annum respectively. EPS is expected to grow by 19.9% per annum. Return on equity is forecast to be 21.2% in 3 years.

Key information

20.9%

Earnings growth rate

19.9%

EPS growth rate

Biotechs earnings growth	29.8%
Revenue growth rate	13.3%
Future return on equity	21.2%
Analyst coverage	Good
Last updated	12 Aug 2024

Recent future growth updates

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Earnings and Revenue Growth Forecasts

NasdaqCM:CPRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	642	222	261	N/A	5
12/31/2025	556	174	211	227	7
12/31/2024	474	137	173	202	7
6/30/2024	434	68	79	197	N/A
3/31/2024	411	65	46	163	N/A
12/31/2023	398	71	-136	144	N/A
9/30/2023	348	62	-114	128	N/A
6/30/2023	303	116	-48	124	N/A
3/31/2023	256	99	-53	120	N/A
12/31/2022	214	83	106	116	N/A
9/30/2022	192	67	85	95	N/A
6/30/2022	170	54	75	76	N/A
3/31/2022	154	45	65	65	N/A
12/31/2021	141	39	59	60	N/A
9/30/2021	134	42	53	54	N/A
6/30/2021	127	75	43	44	N/A
3/31/2021	120	72	41	42	N/A
12/31/2020	119	75	45	45	N/A
9/30/2020	118	71	44	44	N/A
6/30/2020	120	42	49	49	N/A
3/31/2020	119	43	50	50	N/A
12/31/2019	102	32	35	35	N/A
9/30/2019	73	9	14	14	N/A
6/30/2019	42	-12	-9	-9	N/A
3/31/2019	13	-29	-28	-28	N/A
12/31/2018	1	-34	-26	-26	N/A
9/30/2018	N/A	-25	-22	-22	N/A
6/30/2018	N/A	-21	-18	-18	N/A
3/31/2018	N/A	-19	N/A	-16	N/A
12/31/2017	N/A	-18	N/A	-14	N/A
9/30/2017	N/A	-17	N/A	-14	N/A
6/30/2017	N/A	-17	N/A	-15	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-20	N/A	-18	N/A
6/30/2016	N/A	-20	N/A	-20	N/A
3/31/2016	N/A	-20	N/A	-20	N/A
12/31/2015	N/A	-20	N/A	-18	N/A
9/30/2015	N/A	-18	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-16	N/A
3/31/2015	N/A	-17	N/A	-14	N/A
12/31/2014	N/A	-16	N/A	-13	N/A
9/30/2014	N/A	-13	N/A	-13	N/A
6/30/2014	N/A	-14	N/A	-11	N/A
3/31/2014	N/A	-14	N/A	-10	N/A
12/31/2013	N/A	-12	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPRX's forecast earnings growth (20.9% per year) is above the savings rate (2.5%).

Earnings vs Market: CPRX's earnings (20.9% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CPRX's revenue (13.3% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: CPRX's revenue (13.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CPRX's Return on Equity is forecast to be high in 3 years time (21.2%)

Catalyst Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 16%

Price target increased by 8.4% to US$29.57

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Recent updates

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock